Citations

Clear

9383 citation(s) found for "Thomas, PS".

Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma
Ishmael, Leah , Casale, Thomas B. , Cardet, Juan Carlos , Casale, Thomas

Mayo Clinic

Biology | August 1, 2024 | Volume: 13 | Issue: 8 | Pages: 583

10.3390/biology13080583 | PMID 39194521 Get It

Asthma is a chronic inflammatory lung disease. Refractory asthma poses a significant challenge in management due to its resistance to standard therapies. Key molecular pathways of refractory asthma include T2 inflammation mediated by Th2 and ILC2 cells, eosinophils, and cytokines including IL-4, IL-5, and IL-13. Additionally, non-T2 mechanisms involving neutrophils, macrophages, IL-1, IL-6, and IL-17 mediate a corticosteroid resistant phenotype. Mediators including alarmins (IL-25, IL-33, TSLP) and OX40L have overlap between T2 and non-T2 inflammation and may signify unique pathways of asthma inflammation. Therapies that target these pathways and mediators have proven to be effective in reducing exacerbations and improving lung function in subsets of severe asthma patients. However, there are patients with severe asthma who do not respond to approved therapies. Small molecule inhibitors, such as JAK-inhibitors, and monoclonal antibodies targeting mast cells, IL-1, IL-6, IL-33, TNFα, and OX40L are under investigation for their potential to modulate inflammation involved in refractory asthma. Understanding refractory asthma heterogeneity and identifying mediators involved are essential in developing therapeutic interventions for patients unresponsive to currently approved biologics. Further investigation is needed to develop personalized treatments based on these molecular insights to potentially offer more effective treatments for this complex disease.
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
Tocchetti, Carlo G. , Farmakis, Dimitrios , Koop, Yvonne , Andrés, María Sol , Formisano, Luigi , Ciardiello, Fortunato, Emmerich, Max , Plummer, Chris , Gulati, Geeta , Ramalingam, Sivatharshini , Brezden‐Masley, Christine , Iakobishvili, Zaza , Bergler‐Klein, Jutta , Boer, Rudolf A. de , Rassaf, Tienush, Fradley, Michael G. , Moslehi, Javid J. , Yang, Eric H., Neilan, Tomas G. , Herrmann, Joerg , Mirabel, Mariana , Skouri, Hadi , Cohen‐Solal, Alain , Sverdlov, Aaron L. , Meer, Peter van der, Asteggiano, Riccardo , Ky, Bonnie , Seferović, Petar , Metra, Marco , Rosano, Giuseppe, Suter, Thomas, Tocchetti, Carlo Gabriele , López-Fernández, Teresa , de Boer, Rudolf A , Ky, Bonnie , Sverdlov, Aaron L , Metra, Marco , Couch, Liam Steven , Ciardiello, Fortunato , Pane, Fabrizio , Au, Lewis , Cardinale, Daniela , Thavendiranathan, Paaladinesh , Santoro, Ciro , Keramida, Kalliopi , Maack, Christoph , Lutgens, Esther , Rassaf, Tienush , Yang, Eric H., Keulenaer, Gilles W. De , Ameri, Pietro , Bax, Jeroen J. , Mbakwem, Amam , Hirsch, Emilio , Meer, Peter van der , Barac, Ana , Lenihan, Daniel , Dent, Susan , Coats, Andrew J.S. , López‐Fernández, Teresa , Lyon, Alexander R.

Mayo Clinic

European Journal of Heart Failure | August 1, 2024 | Volume: 26 | Issue: 10 | Pages: 2055-2076

10.1002/ejhf.3340 | PMID 39087551 Get It

ABSTRACT The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can be broadly divided into two classes. The first class are antibodies that inhibit immune checkpoint signalling, known as immune checkpoint inhibitors (ICIs). The second class are cell-based immune therapies including chimeric antigen receptor T lymphocyte (CAR-T) cell therapies, natural killer (NK) cell therapies, and tumour infiltrating lymphocyte (TIL) therapies. The clinical efficacy of all these treatments generally outweighs the risks, but there is a high rate of immune-related adverse events (irAEs), which are often unpredictable in timing with clinical sequalae ranging from mild (e.g. rash) to severe or even fatal (e.g. myocarditis, cytokine release syndrome) and reversible to permanent (e.g. endocrinopathies).The mechanisms underpinning irAE pathology vary across different irAE complications and syndromes, reflecting the broad clinical phenotypes observed and the variability of different individual immune responses, and are poorly understood overall. Immune-related cardiovascular toxicities have emerged, and our understanding has evolved from focussing initially on rare but fatal ICI-related myocarditis with cardiogenic shock to more common complications including less severe ICI-related myocarditis, pericarditis, arrhythmias, including conduction system disease and heart block, non-inflammatory heart failure, takotsubo syndrome and coronary artery disease. In this scientific statement on the cardiovascular toxicities of immune therapies for cancer, we summarize the pathophysiology, epidemiology, diagnosis, and management of ICI, CAR-T, NK, and TIL therapies. We also highlight gaps in the literature and where future research should focus.
Intracranial Atherosclerotic Disease and Incident Dementia: The ARIC Study (Atherosclerosis Risk in Communities)
Zhao, Di , Güallar, Eliseo , Qiao, Ye , Knopman, David S. , Palatino, Maylin, Mosley, Thomas H. , Wasserman, Bruce A. , Mosley, Thomas H. , Knopman, David S. , Gottesman, Rebecca F , Wasserman, Bruce A , Guallar, Eliseo , Gottesman, Rebecca F.

Mayo Clinic

Circulation | August 1, 2024 | Volume: 150 | Issue: 11 | Pages: 838-847

10.1161/circulationaha.123.067003 | PMID 39087353 Get It

BACKGROUND: Studies of the neurovascular contribution to dementia have largely focused on cerebral small vessel disease (CSVD), but the role of intracranial atherosclerotic disease (ICAD) remains unknown in the general population. The objective of this study was to determine the risk of incident dementia from ICAD after adjusting for CSVD and cardiovascular risk factors in a US community-based cohort. METHODS: We acquired brain magnetic resonance imaging examinations from 2011 through 2013 in 1980 Black and White participants in the ARIC study (Atherosclerosis Risk in Communities), a prospective cohort conducted in 4 US communities. Magnetic resonance imaging examinations included high-resolution vessel wall magnetic resonance imaging and magnetic resonance angiography to identify ICAD. Of these participants, 1590 without dementia, without missing covariates, and with adequate magnetic resonance image quality were followed through 2019 for incident dementia. Associations between ICAD and incident dementia were assessed using Cox proportional hazard ratios adjusted for CSVD (characterized by white matter hyperintensities, lacunar infarctions, and microhemorrhages), APOE4 genotype (apolipoprotein E gene ε4), and cardiovascular risk factors. RESULTS: The mean age (SD) of study participants was 77.4 (5.2) years. ICAD was detected in 34.6% of participants. After a median follow-up of 5.6 years, 286 participants developed dementia. Compared with participants without ICAD, the fully adjusted hazard ratios (95% CIs) for incident dementia in participants with any ICAD, with ICAD only causing stenosis ≤50%, and with ICAD causing stenosis >50% in ≥1 vessel were 1.57 (1.17–2.11), 1.41 (1.02–1.95), and 1.94 (1.32–2.84), respectively. ICAD was associated with dementia even among participants with low white matter hyperintensities burden, a marker of CSVD. CONCLUSIONS: ICAD was associated with an increased risk of incident dementia, independent of CSVD, APOE4 genotype, and cardiovascular risk factors. The increased risk of dementia was evident even among participants with low CSVD burden, a group less likely to be affected by vascular dementia, and in participants with ICAD causing only low-grade stenosis. Our results suggest that ICAD may partially mediate the effect that cardiovascular risk factors have on the brain leading to dementia. Both ICAD and CSVD must be considered to understand the vascular contributions to cognitive decline.
A novel structured, volume‐based, weight‐loss and health programme combined with respiratory muscle training helps reduce weight and cardiovascular risk in people with obesity
Woodard, J., Boeder, MiKinze, Turinske, Thomas J., Stiles, Ashley, Lipset, Max, Bausek, Nina , Bausek, Nina , Woodard, Jacob, Meyer, Nicholas J.

Mayo Clinic

Diabetes, Obesity and Metabolism | July 31, 2024 | Volume: 26 | Issue: 10 | Pages: 4772-4775

10.1111/dom.15795 | PMID 39082073 Get It

Sex disparities in cardiac sarcoidosis patients undergoing implantable cardioverter‐defibrillator implantation
Ahmed, Raheel , Jamil, Yumna , Ramphul, Kamleshun , Mactaggart, Sebastian , Bilal, Maham , Shi, Rui , Azzu, Alessia , Memon, Rahat A , Sakthivel, Hemamalini, Khattar, Rajdeep , Wells, Athol U. , Baksi, John Arun, Wechalekar, Kshama , Sharma, Rakesh, Ahmed, Raheel , Dulay, Mansimran Singh , Okafor, Joseph , Kouranos, Vasileios , Chahal, C. Anwar A.

Mayo Clinic

Pacing and Clinical Electrophysiology | July 30, 2024 | Volume: 47 | Issue: 10 | Pages: 1394-1403

10.1111/pace.15051 | PMID 39078380 Get It

AbstractIntroductionIn patients with cardiac sarcoidosis (CS), implantable cardioverter‐defibrillators (ICDs) are important for preventing sudden cardiac death. This study aimed to investigate sex disparities in CS patients undergoing ICD implantation.MethodsThe 2016–2020 National Inpatient Sample (NIS) database compared the characteristics and outcomes of males and females with CS receiving ICDs.ResultsAmong 760 CS patients who underwent inpatient ICD implantation, 66.4% were male. Males were younger (55.0 vs. 56.9 years, p < .01), had higher rates of diabetes (31.7% vs. 21.6%, p < .01) and chronic kidney disease (CKD) (16.8% vs. 7.8%, p < .01) but lower prevalence of atrial fibrillation (AF) (11.9% vs. 23.5%, p < .01), sick sinus syndrome (4.0% vs. 7.8%, p = .024), ventricular fibrillation (VF) (9.9% vs. 15.7%, p = .02), and black ancestry (31.9% vs. 58.0%, p < .01). Unadjusted major adverse cardiovascular events (MACE), defined as a composite of in‐hospital death, myocardial infarction (MI), and ischemic stroke, was higher in females (11.8% vs. 6.9%, p = .024), but when adjusted for age and tCharlson Comorbidity Index (CCI), females demonstrated significantly lower odds of experiencing MACE (aOR: 0.048, 95% CI: 0.006–0.395, p = .005). Incidence of acute kidney injury (AKI) post‐ICD was significantly lower in females (15.7% vs. 23.8%, p = .01) as was the adjusted odds (aOR: 0.282, 95% CI: 0.146–0.546, p < .01). There was comparable mean length of stay and hospital charges.ConclusionICD utilization in CS patients is more common among males, who have a higher prevalence of diabetes and CKD but a lower prevalence of AF, sick sinus syndrome, and VF. Adjusted MACE and AKI were significantly lower in females.
Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study
Curtis, K., Fakult, Nathan J., Strunck, Jennifer L. , Aasi, Sumaira Z. , Ahn, Christine , Alam, Murad, Bar, Anna, Behshad, Ramona, Bichakjian, Christopher K. , Bolotin, Diana, Boone, Susan L., Brewer, Jerry D., Carr, David R. , Castillo, Jason R., Christensen, Sean R. , Clark, Melanie A., Collins, Lindsey K., Demer, Addison M. , Eisen, Daniel B. , Feng, Hao , Firoz, Bahar, Grekin, Roy C. , Hirshburg, Jason M., Holmes, Todd, Huang, Conway C. , Jennings, Thomas , Konda, Sailesh , Leitenberger, Justin J. , Lewin, Jesse M., Ng, Elise, Orengo, Ida, Samie, Faramarz H. , Saylor, Drew K. , Soleymani, Teo, Tate, Jesalyn A. , Vidal, Nahid Y. , Vij, Alok , Wysong, Ashley , Xu, Yaohui G. , Carroll, Bryan T. , Curtis, Kristen K., Bordeaux, Jeremy S. , Carr, David R., Carucci, John A. , Jiang, Shang I. Brian , Maher, Ian A. , Sharon, Victoria R. , Swetter, Susan M. , Beek, Marta J. Van , Yu, Wesley Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 30, 2024 | Volume: 22 | Issue: 8 | Pages: No page available

10.6004/jnccn.2024.7036 | PMID 39079545 Get It

Background: Mohs micrographic surgery (MMS) is a promising treatment modality for melanoma in situ (MIS). However, variations in surgical technique limit the generalizability of existing data and may impede future study of MMS in clinical trials. Methods: A modified Delphi method was selected to establish consensus on optimal MMS techniques for treating MIS in future clinical trials. The Delphi method was selected due to the limited current data, the wide range of techniques used in the field, and the intention to establish a standardized technique for future clinical trials. A literature review and interviews with experienced MMS surgeons were performed to identify dimensions of the MMS technique for MIS that (1) likely impacted costs or outcomes of the procedure, and (2) showed significant variability between surgeons. A total of 8 dimensions of technical variation were selected. The Delphi process consisted of 2 rounds of voting and commentary, during which 44 expert Mohs surgeons across the United States rated their agreement with specific recommendations using a Likert scale. Results: Five of eight recommendations achieved consensus in Round 1. All 3 of the remaining recommendations achieved consensus in Round 2. Techniques achieving consensus in Round 1 included the use of a starting peripheral margin of ≤5 mm, application of immunohistochemistry, frozen tissue processing, and resecting to the depth of subcutaneous fat. Consensus on the use of Wood’s lamp, dermatoscope, and negative tissue controls was established in Round 2. Conclusions: This study generated 8 consensus recommendations intended to offer guidance for Mohs surgeons treating MIS. The adoption of these recommendations will promote standardization to facilitate comparisons of aggregate data in multicenter clinical trials.
Pretreatment predictors of very poor clinical outcomes in medium vessel occlusion stroke patients treated with mechanical thrombectomy
Yedavalli, Vivek , Salim, Hamza , Adeeb, Nimer , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Kühn, Anna Luisa, Khalife, Jane, Ghozy, Sherief, Tan, Benjamin Yong‐Qiang , Heit, Jeremy J. , Regenhardt, Robert W. , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil, Essibayi, Muhammed Amir , Puri, Ajit S , Dyzmann, Christian , Colasurdo, Marco , Barreau, Xavier , Filipe, João Pedro , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S., Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Liebeskind, David S. , Henninger, Nils , Tan, Benjamin Yq , Cancelliere, Nicole M , Alexandru Radu, Răzvan , Ota, Takahiro , Jabbour, Pascal , Clarençon, Frédéric , Siegler, James E , Nguyen, Thanh N , Gonzalez, Nestor R , Pedicelli, Alessandro , Alexandre, Andrea M , Guenego, Adrien , Dmytriw, Adam A , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Salim, Hamza , Regenhardt, Robert W , Essibayi, Muhammed Amir , Yedavalli, Vivek S , Rouchaud, Aymeric , Colasurdo, Marco , Varela, Ricardo , Musmar, Basel , Naamani, Kareem El , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Bernstock, Joshua D. , Fiehler, Jens , Sheth, Sunil A , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

International Journal of Stroke | July 30, 2024 | Volume: 19 | Issue: 10 | Pages: 1123-1133

10.1177/17474930241270524 | PMID 39075759 Get It

Background: Acute ischemic stroke (AIS) from primary medium vessel occlusions (MeVO) is a prevalent condition associated with substantial morbidity and mortality. Despite the common use of mechanical thrombectomy (MT) in AIS, predictors of poor outcomes in MeVO remain poorly characterized. Methods: In this prospectively collected, retrospectively reviewed, multicenter, multinational study, data from the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry were analyzed. The study included 1568 patients from 37 academic centers across North America, Asia, and Europe, treated with MT, with or without intravenous tissue plasminogen activator (IVtPA), between September 2017 and July 2021. Results: Among the 1568 patients, 347 (22.2%) experienced very poor outcomes (modified Rankin score (mRS), 5–6). Key predictors of poor outcomes were advanced age (odds ratio (OR): 1.03; 95% confidence interval (CI): 1.02 to 1.04; p < 0.001), higher baseline National Institutes of Health Stroke Scale (NIHSS) scores (OR: 1.07; 95% CI: 1.05 to 1.10; p < 0.001), pre-operative glucose levels (OR: 1.01; 95% CI: 1.00 to 1.02; p < 0.001), and a baseline mRS of 4 (OR: 2.69; 95% CI: 1.25 to 5.82; p = 0.011). The multivariable model demonstrated good predictive accuracy with an area under the receiver-operating characteristic (ROC) curve of 0.76. Conclusions: This study demonstrates that advanced age, higher NIHSS scores, elevated pre-stroke mRS, and pre-operative glucose levels significantly predict very poor outcomes in AIS-MeVO patients who received MT. These findings highlight the importance of a comprehensive risk assessment in primary MeVO patients for personalized treatment strategies. However, they also suggest a need for cautious patient selection for endovascular thrombectomy. Further prospective studies are needed to confirm these findings and explore targeted therapeutic interventions.
Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia
Pike, James Russell , Chen, Jinyu , Sullivan, Kevin , Thyagarajan, Bharat , Lutsey, Pamela L. , Sharrett, A. Richey, Mosley, Thomas H., Palta, Priya, Sullivan, Kevin J , Lutsey, Pamela L , Pike, James R , Thyagarajan, Bharat , Lü, Yifei , Walker, Keenan A. , Mielke, Michelle M. , Knopman, David S. , Gottesman, Rebecca F. , Coresh, Josef , Mosley, Thomas H.

Mayo Clinic

JAMA | July 28, 2024 | Volume: 332 | Issue: 15 | Pages: 1258

10.1001/jama.2024.6619 | PMID 39068543 Get It

Importance Plasma biomarkers show promise for identifying Alzheimer disease (AD) neuropathology and neurodegeneration, but additional examination among diverse populations and throughout the life course is needed. Objective To assess temporal plasma biomarker changes and their association with all-cause dementia, overall and among subgroups of community-dwelling adults. Design, Setting, and Participants In 1525 participants from the US-based Atherosclerosis Risk in Communities (ARIC) study, plasma biomarkers were measured using stored specimens collected in midlife (1993-1995, mean age 58.3 years) and late life (2011-2013, mean age 76.0 years; followed up to 2016-2019, mean age 80.7 years). Midlife risk factors (hypertension, diabetes, lipids, coronary heart disease, cigarette use, and physical activity) were assessed for their associations with change in plasma biomarkers over time. The associations of biomarkers with incident all-cause dementia were evaluated in a subpopulation (n = 1339) who were dementia-free in 2011-2013 and had biomarker measurements in 1993-1995 and 2011-2013. Exposure Plasma biomarkers of amyloid-β 42 to amyloid-β 40 (Aβ42:Aβ40) ratio, phosphorylated tau at threonine 181 (p-tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were measured using the Quanterix Simoa platform. Main Outcomes and Measures Incident all-cause dementia was ascertained from January 1, 2012, through December 31, 2019, from neuropsychological assessments, semiannual participant or informant contact, and medical record surveillance. Results Among 1525 participants (mean age, 58.3 [SD, 5.1] years), 914 participants (59.9%) were women, and 394 participants (25.8%) were Black. A total of 252 participants (16.5%) developed dementia. Decreasing Aβ42:Aβ40 ratio and increasing p-tau181, NfL, and GFAP were observed from midlife to late life, with more rapid biomarker changes among participants carrying the apolipoprotein E epsilon 4 ( APOE ε4) allele. Midlife hypertension was associated with a 0.15-SD faster NfL increase and a 0.08-SD faster GFAP increase per decade; estimates for midlife diabetes were a 0.11-SD faster for NfL and 0.15-SD faster for GFAP. Only AD-specific biomarkers in midlife demonstrated long-term associations with late-life dementia (hazard ratio per SD lower Aβ42:Aβ40 ratio, 1.11; 95% CI, 1.02-1.21; per SD higher p-tau181, 1.15; 95% CI, 1.06-1.25). All plasma biomarkers in late life had statistically significant associations with late-life dementia, with NfL demonstrating the largest association (1.92; 95% CI, 1.72-2.14). Conclusions and Relevance Plasma biomarkers of AD neuropathology, neuronal injury, and astrogliosis increase with age and are associated with known dementia risk factors. AD-specific biomarkers’ association with dementia starts in midlife whereas late-life measures of AD, neuronal injury, and astrogliosis biomarkers are all associated with dementia.
Assessing knowledge gaps and educational needs in urine drug test interpretation among health care professionals
Snozek, Christine L.H. , Yee, Claire I., Bryksin, Janetta, Dahal, Rejwi , Gerson, Benjamin, Gherasim, Carmen , Heger, Nicholas E. , Johnson‐Davis, Kamisha L. , Knezevic, Claire E. , Love, Sara A., Noguez, Jaime H. , Pikulski, Michael, Tyagi, Manoj , Warrington, Jill S. , Yang, He S. , Yang, Yifei , Knezevic, Claire E , Roper, Stephen , Yang, Yifei K, Hauff, Kristin D. , Huestis, Marilyn Ann , Melanson, Stacy E.F. , Roper, Stephen M. , Tyagi, Manoj

Mayo Clinic

American Journal of Clinical Pathology | July 27, 2024 | Volume: 163 | Issue: 1 | Pages: 69-79

10.1093/ajcp/aqae095 | PMID 39066575 Get It

Abstract Objectives Urine drug testing (UDT) is a critical tool used in medical, forensic, and occupational settings, but interpreting results can be challenging. We performed a study to assess the ability of health care professionals to interpret UDT results accurately. Methods In total, 911 clinical and laboratory professionals in the United States and Canada responded to a survey with questions gauging expertise in UDT interpretation. Responses were analyzed to identify knowledge gaps. Results Toxicologists and laboratory PhD scientists performed well, with means of 4.82 and 4.63 questions answered correctly (out of 6 possible), respectively. Physicians specializing in pathology, emergency medicine, primary care, and internal medicine, however, displayed concerning knowledge gaps, as did laboratorians with nondoctoral degrees. Experience and training correlated with interpretation accuracy. Identification of simulated compliance as well as understanding opioid exposure, metabolism, and immunoassay cross-reactivity were among the most clinically significant knowledge gaps. More than 30% of survey respondents indicated that they would seek UDT information from the internet or peers rather than clinical or laboratory experts. Conclusions The study highlighted the need for targeted education and better collaboration between clinical and laboratory experts and other health care professionals to ensure that when physicians order UDT, they can accurately interpret results and reduce harm.
The COVID‐19 pandemic as a modifier of DGBI symptom severity: A systematic review and meta‐analysis
Kulin, Dmitrii , Shah, Ayesha , Fairlie, Thomas, Wong, Reuben K. , Fang, Xiucai , Ghoshal, Uday C. , Kashyap, Purna , Mulak, Agata , Lee, Yeong Yeh , Talley, Nicholas J. , Jones, Michael , Holtmann, Gerald , Talley, Nicholas J. , Kashyap, Purna C , Koloski, Natasha , Jones, Michael P , Holtmann, Gerald J , Ghoshal, Uday C , Mulak, Agata , Lee, Yeong Yeh

Mayo Clinic

Neurogastroenterology & Motility | July 26, 2024 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/nmo.14878 | PMID 39056447 Get It

AbstractBackgroundThis SRMA reviewed and assessed the changes in the severity of disorders of gut‐brain interaction (DGBI) symptoms during the COVID‐19 pandemic, and evaluated factors associated with symptom severity changes.MethodsElectronic databases were searched until February 2024, for articles reporting on changes in symptom severity in DGBI patients during the COVID‐19 pandemic. The proportion of DGBI patients who reported a change in their symptom severity were pooled using a random‐effects model, and subgroup analyses were conducted to assess the effect of socio‐cultural modifiers on symptom severity in DGBI.Key ResultsTwelve studies including 3610 DGBI patients found that 31.4% (95% CI, 15.9–52.5) of DGBI patients experienced symptom deterioration, while 24.3% (95% CI, 10.2–47.5) experienced improvement. Countries with high gross domestic product (GDP) had a 43.5% (95% CI, 16.3–75.2) likelihood of symptom deterioration, compared to 9.2% (95% CI, 1.4–42.2) in lower GDP countries. Similarly, countries with low COVID fatality rates had a 60.1% (95% CI, 19.7–90.3) likelihood of symptom deterioration, compared to 18.3% (95% CI, 7.8–36.9) in higher fatality rate countries. Countries with lenient COVID policies had a 58.4% (95% CI, 14.1–92.3) likelihood of symptom deterioration, compared to 19% (95% CI, 8.2–38.1) in countries with stricter policies. Patients in high vaccine hesitancy countries had a 51.4% (95% CI, 19.5–82.2) likelihood of symptom deterioration, compared to 10.6% (95% CI, 2.7–33.4) in low vaccine hesitancy countries.Conclusions & InferencesThis meta‐analysis reveals that a significantly higher proportion of DGBI patients experienced deterioration of symptoms during the COVID‐19 pandemic. Various sociocultural, economic and environmental factors potentially modify the effects of the COVID‐19 pandemic on DGBI.